Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)

Abstract Introduction Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient-reported outcomes (PROs) among adults and a...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Eric L. Simpson, Vimal H. Prajapati, Yael A. Leshem, Raj Chovatiya, Marjolein S. de Bruin-Weller, Sonja Ständer, Andrew E. Pink, Brian M. Calimlim, Wan-Ju Lee, Henrique Teixeira, Barry Ladizinski, Xiaofei Hu, Yang Yang, Yingyi Liu, Meng Liu, Ayman Grada, Andrew M. Platt, Jonathan I. Silverberg
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2024-05-01
Serie:	Dermatology and Therapy
Soggetti:	Atopic dermatitis Itch Patient-reported outcome measures Quality of life Randomized controlled trials Upadacitinib
Accesso online:	https://doi.org/10.1007/s13555-024-01157-5
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!